These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51. In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Crooke RM Anticancer Drug Des; 1991 Dec; 6(6):609-46. PubMed ID: 1772572 [TBL] [Abstract][Full Text] [Related]
52. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment. Soler M; McHutchison JG; Kwoh TJ; Dorr FA; Pawlotsky JM Antivir Ther; 2004 Dec; 9(6):953-68. PubMed ID: 15651754 [TBL] [Abstract][Full Text] [Related]
53. Inhibition of syncytium formation by antisense oligonucleotide phosphorothioates complementary to tax mRNA of human T-cell leukemia virus type 1 (HTLV-1). Maeda N; Hoshino H; Kushida S; Miyano-Kurosaki N; Yamamoto N; Yokota T; Mizuguchi M; Makino K; Uchida K; Miwa M Leukemia; 1997 Apr; 11 Suppl 3():42-4. PubMed ID: 9209291 [TBL] [Abstract][Full Text] [Related]
54. Targeting the expression of anti-apoptotic proteins by antisense oligonucleotides. Delihas N Curr Drug Targets; 2001 Jun; 2(2):167-80. PubMed ID: 11469717 [TBL] [Abstract][Full Text] [Related]
55. Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology. Jepsen JS; Sørensen MD; Wengel J Oligonucleotides; 2004; 14(2):130-46. PubMed ID: 15294076 [TBL] [Abstract][Full Text] [Related]
56. Sugar boost: when ribose modifications improve oligonucleotide performance. Faria M; Ulrich H Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229 [TBL] [Abstract][Full Text] [Related]